secwatch.observer — SEC 8-K summary
======================================

Issuer:     ANAPTYSBIO, INC (ANAB)
CIK:        0001370053
Form:       8-K
Filed at:   2024-01-05T23:59:59+00:00
Accession:  0001370053-24-000003
Event type: other_material
Sentiment:  positive
Materiality: 0.50
Item codes: 2.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

AnaptysBio expects $417M cash at year-end 2023; presents at JPM Healthcare Conference
--------------------------------------------------------------------------------

- Preliminary cash, cash equivalents, and investments of approximately $417M as of December 31, 2023.
- Presentation at J.P. Morgan Healthcare Conference on January 8, 2024; full corporate overview furnished as Exhibit 99.1.
- Audited FY2023 financials not yet available; preliminary estimate subject to adjustment.
- Presentation details (pipeline, clinical data) not fully available in the provided exhibit excerpt.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1370053/000137005324000003/0001370053-24-000003-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1370053/000137005324000003/anab-20240105.htm
  HTML page:      https://secwatch.observer/filing/0001370053-24-000003

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer